C.M. Bidwell & Associates’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-52
| Closed | -$5.57K | – | 493 |
|
|
2024
Q4 | $5.57K | Hold |
52
| – | – | ﹤0.01% | 318 |
|
|
2024
Q3 | $5.21K | Hold |
52
| – | – | ﹤0.01% | 323 |
|
|
2024
Q2 | $4.38K | Hold |
52
| – | – | ﹤0.01% | 333 |
|
|
2024
Q1 | $3.8K | Hold |
52
| – | – | ﹤0.01% | 353 |
|
|
2023
Q4 | $3.71K | Buy |
52
+22
| +73% | +$1.57K | ﹤0.01% | 356 |
|
|
2023
Q3 | $1.8K | Sell |
30
-1,241
| -98% | -$74.4K | ﹤0.01% | 479 |
|
|
2023
Q2 | $91.6K | Buy |
1,271
+1,256
| +8,373% | +$90.6K | 0.07% | 251 |
|
|
2023
Q1 | $1.1K | Buy |
+15
| New | +$1.1K | ﹤0.01% | 492 |
|
|
2020
Q4 | – | Sell |
-1,111
| Closed | -$66K | – | 512 |
|
|
2020
Q3 | $66K | Sell |
1,111
-3,169
| -74% | -$188K | 0.06% | 231 |
|
|
2020
Q2 | $299K | Buy |
+4,280
| New | +$299K | 0.27% | 80 |
|
|
2019
Q2 | – | Sell |
-1,755
| Closed | -$138K | – | 428 |
|
|
2019
Q1 | $138K | Buy |
+1,755
| New | +$138K | 0.14% | 154 |
|
|
2018
Q4 | – | Sell |
-409
| Closed | -$70K | – | 431 |
|
|
2018
Q3 | $70K | Sell |
409
-8
| -2% | -$1.37K | 0.07% | 212 |
|
|
2018
Q2 | $54K | Hold |
417
| – | – | 0.05% | 240 |
|
|
2018
Q1 | $43K | Buy |
+417
| New | +$43K | 0.04% | 248 |
|